Cytokinetics, Incorporated
CYTK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5 | $8 | $4 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $6 | $9 | $5 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 145.3% | -92% | 34.3% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,737.2% | -4,284.1% | -154.6% | -127.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,671.2% | -6,064.9% | -348.2% | -250.4% |
| Net Income | -$1 | -$1 | -$0 | -$0 |
| % Margin | -3,191.1% | -6,988.6% | -411.2% | -305.7% |
| EPS Diluted | -5.26 | -5.45 | -4.33 | -2.8 |
| % Growth | 3.5% | -25.9% | -54.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |